PT  - JOURNAL ARTICLE
AU  - Valeria Chu
AU  - Heidi J. Einolf
AU  - Raymond Evers
AU  - Gondi Kumar
AU  - David Moore
AU  - Sharon Ripp
AU  - Jose Silva
AU  - Vikram Sinha
AU  - Michael Sinz
AU  - Andrej Skerjanec
TI  - In Vitro and in Vivo Induction of Cytochrome P450: A Survey of the Current Practices and Recommendations: A Pharmaceutical Research and Manufacturers of America Perspective
AID  - 10.1124/dmd.109.027029
DP  - 2009 Jul 01
TA  - Drug Metabolism and Disposition
PG  - 1339--1354
VI  - 37
IP  - 7
4099  - http://dmd.aspetjournals.org/content/37/7/1339.short
4100  - http://dmd.aspetjournals.org/content/37/7/1339.full
SO  - Drug Metab Dispos2009 Jul 01; 37
AB  - Cytochrome P450 (P450) induction is one of the factors that can affect the pharmacokinetics of a drug molecule upon multiple dosing, and it can result in pharmacokinetic drug-drug interactions with coadministered drugs causing potential therapeutic failures. In recent years, various in vitro assays have been developed and used routinely to assess the potential for drug-drug interactions due to P450 induction. There is a desire from the pharmaceutical industry and regulatory agencies to harmonize assay methodologies, data interpretation, and the design of clinical drug-drug interaction studies. In this article, a team of 10 scientists from nine Pharmaceutical Research and Manufacturers of America (PhRMA) member companies conducted an anonymous survey among PhRMA companies to query current practices with regards to the conduct of in vitro induction assays, data interpretation, and clinical induction study practices. The results of the survey are presented in this article, along with reviews of current methodologies of in vitro assays and in vivo studies, including modeling efforts in this area. A consensus recommendation regarding common practices for the conduct of P450 induction studies is included.